Introduction
More than 220,000 Americans were diagnosed with lung cancer in 2015, including 15% with localized disease. 1 The incidence of stage I NSCLC is expected to increase despite decreasing numbers of smokers 2 because of an aging population and new screening recommendations. 3 Surgical resection by means of lobectomy 4 is the standard treatment for medically fit and technically resectable patients. Noninvasive procedures, such as radiation, are reserved for inoperable candidates. 5 Technical improvements in the diagnosis and treatment of stage I NSCLC have been implemented in the past two decades. Staging positron emission tomography (PET)-computed tomography scans are now routine. 6 Video-assisted thoracoscopic surgical (VATS) procedures reduce morbidity and hospital stays. 7 Finally, the adoption of radiation treatment schedules using a few precisely targeted high doses, termed stereotactic body radiation therapy (SBRT), is widespread. 8 We sought to determine the impact of these diagnostic, staging, and treatment techniques on outcomes in patients with stage I NSCLC. The Veterans Administration (VA) Central Cancer Registry (VACCR) is a mandatory, audited database of all veterans in whom cancer was diagnosed in the Veterans Health Administration (VHA), the largest hospital system in the United States; it is linked to the VA electronic medical record and other patient-specific databases, thus providing a unique resource to analyze cancer patient outcomes. Given that cancer outcomes in the VHA have been shown to be equivalent to fee-for-service care, 9 we leveraged this resource to perform a population-based analysis of patients with stage I NSCLC that was diagnosed within the Veterans Health Administration from 2001 to 2010.
Materials and Methods

Study Design and Population
The study population consisted of veterans with clinical stage I NSCLC diagnosed on the basis of contemporaneous American Joint Committee on Cancer staging from January 1, 2001, through December 31, 2010. Patients were excluded if treatment started more than 180 days from diagnosis. Demographic, clinical, treatment, and outcome data were obtained from the VACCR, linked to VHA electronic health record data 10 and VHA administrative databases, including the Corporate Data Warehouse (CDW) and the National Death Index. This study was approved by the Durham VA Institutional Review Board.
Measures, Outcomes, and Covariates
Primary outcomes were overall survival (OS) and lung cancer-specific survival (LCSS) calculated from the diagnosis date. Surviving patients were censored on October 21, 2014. For LCSS, analysis was restricted to patients whose NSCLC was diagnosed from 2001 to 2008 and censored on December 31, 2011, because the National Death Index data available captures deaths through that date. Charlson comorbidity index (CCI) was calculated using International Classification of Diseases, Ninth Revision (ICD-9) codes in the year before diagnosis. Diagnostic PET, computed tomography, and chest or endobronchial ultrasound (EBUS) were determined from Current Procedural Terminology (CPT) codes or non-VA care approval 180 days before or after diagnosis and before treatment initiation.
Treatment
Surgery type and radiation fractionation were based on abstracted data in the VACCR or CPT codes (Supplementary Table 1 ) within the CDW. SBRT delivery was validated with CPT code 77373 or CDW data. Patients identified as not having treatment had documentation within CDW indicating such. The ICD-9 codes associated with inpatient and outpatient encounters in the 6 months after treatment were used as a marker of treatment toxicity. The ICD-9 codes used for acute kidney disease, deep vein thrombosis/pulmonary emblism, acute coronary syndrome, stroke, pneumonia, mucositis, radiation pneumonitis, and pneumothorax are shown in Supplementary Table 2 .
Statistical Analysis
Differences in baseline characteristics were tested for by the Pearson c 2 test or t test for categorical and continuous variables, respectively. Survival curves were prepared by the Kaplan-Meier method. Cox proportional hazards modeling and propensity score (PS) adjustment were used to compare survival outcomes adjusted for differences in baseline characteristics.
In the standard Cox model, variables with a p value less than 0.05 in the univariate analysis were included in the multivariate analysis. The proportional hazards assumption was met for each covariate tested. No interaction was found between the treatment regimen and each covariate at a significance level of p less than 0.05. PS analysis was used to adjust for nonrandom treatment assignment for known baseline characteristics. The PS was calculated on the basis of a multiple logistic regression for receiving a given treatment. The model included the following variables: age, race (white versus nonwhite), a diagnosis of chronic obstructive pulmonary disease, CCI, treatment region, year of diagnosis, histologic type (squamous versus nonsquamous), and stage (IA versus IB).
Matched pair analysis was then performed by using the logit of the estimated PS. To compare the groups, a marginal Cox model was applied by using maximum partial likelihood estimates of regression parameters and a robust sandwich covariance matrix. All statistical analyses were carried out with SAS software, version 9.4 (SAS Institute, Cary, NC).
Results
Patient Characteristics
Of the 14,177 patients with stage I NSCLC diagnosed in the VHA from 2001 to 2010, 11,997 were included ( Supplementary Fig. 1 Table 1 ).
Survival by Year of Diagnosis
Interestingly, we noted an absolute 14% increase in 4-year OS of all patients with stage I NSCLC (from 38.9% in 2001 to 53.2% in 2010) (p < 0.001) (Fig. 1A ). In the radiation cohort, 4-year OS more than doubled (from 12.7% to 28.5% [p < 0.001]). For surgical patients, 4-year OS improved from 51.5% to 66.5% (p < 0.001). As a control, there was no statistically significant difference in 4-year OS in patients not receiving treatment (p ¼ 0.56) (see Fig. 1A ). Survival outcomes were not associated with either average time to treatment or hospital volume (Supplementary Fig. 2A and B).
Effect of Staging with PET and EBUS on Outcomes
As improved survival could be related to increasing use of advanced staging techniques, we evaluated the impact of PET and EBUS on outcomes. Utilization of diagnostic PET increased from 8.2% to 67.8% and from 12.0% to 69.8% in the surgery and radiation groups, respectively, from 2001 to 2010 (p < 0.001 for both [ Supplementary Fig. 3A] ). Compared with the OS in patients who did not undergo PET, OS with the addition of diagnostic PET was longer in both the surgery (hazard ratio Fig. 3C ). EBUS was also introduced during this period, and the 102 surgical patients (1.2% of the total) undergoing this procedure had an improved OS compared with those who did not (HR ¼ 0.72, 95% CI: 0.53-0.98, p ¼ 0.034) ( Supplementary Fig. 3D ).
Improved Survival with Increased Utilization of SBRT
We next investigated change in radiation practice patterns as a possible explanation for the more than doubling of OS within this cohort. We noted increased SBRT utilization (from 4.9% to 60.3%) (Fig. 1B) . Furthermore, we found that SBRT was associated with improved OS (HR ¼ 0.60, 95% CI: 0.54-0.68, p < 0.001) ( Table 5 ).
The OS benefit of SBRT persisted on Cox multivariate analysis (HR ¼ 0.72, p < 0.001), whereas the diagnosis era (HR ¼ 0.93, p ¼ 0.32) and PET staging (HR ¼ 0.88, p ¼ 0.084) (Supplementary Table 6 ) did not. Additionally, when patients were PS-matched, OS remained significantly greater with SBRT than with CRT (HR ¼ 0.62, 95% CI: 0.54-0.72, p < 0.001) (see Supplementary Fig. 4 ). These data therefore indicate that SBRT was responsible for the observed increase in OS within the radiation cohort.
Effect of VATS Procedures on Survival
We next sought to explain the 15% absolute increase in 4-year OS in surgical patients. We hypothesized that the increased OS was due to increasing use of surgical techniques with decreased surgical morbidity and equivalent or increased cancer control. Given the known effect of surgical volume on outcomes, we analyzed survival by surgical volume and found no differences (see Supplementary Fig. 2B ). Within the surgery cohort, most patients underwent an open lobectomy (67.1%) versus open sublobar resection (14.6%), VATS lobectomy (7.8%), VATS sublobar resection (5.9%), or pneumonectomy (2.9%). As OS was equivalent between segmentectomy and wedge procedures (HR ¼ 0.96, p ¼ 0.63) ( Supplementary Fig. 5A ), we grouped them together as sublobar resections.
We noted that from 2001 to 2010, the rate of VATS lobectomy increased from 0.9% to 17.3% and the VATS sublobar rate increased from 1.5% to 11.7% ( Fig. 2A) . 2D and Supplementary Fig. 5B ).
Effect of Extent of Resection on Survival
We subsequently sought to determine whether extent of anatomic resection influenced the OS of all surgical patients. From 2001 to 2010, the sublobar resection rate increased from 16.4% to 25.6% (see Fig. 2A Table 7 ). The complete resection rate or nodal staging rate did not change with time ( Supplementary Fig. 5C and D, respectively). On PS-matched analysis including pathologic nodal stage and margin status, the OS improvement in patients who underwent lobectomy persisted (HR ¼ 0.82, 95% CI: 0.75-0.89, p < 0.001) (Fig. 3A) .
The annual pneumonectomy rate decreased from 3.6% to 1.0% from 2001 to 2010 (see Fig. 2A ). OS was worse with pneumonectomy on univariate (HR ¼ 1.48, p < 0.001) (see Fig. 2B ) and PS-matched (HR ¼ 1.33, p ¼ 0.008) (Supplementary Fig. 5E ) analysis. Consistent with this finding, 90-day mortality was 2.8% in all surgical patients and 8.2% in patients who underwent pneumonectomy (p < 0.001) (see Supplementary Table 4 ). There were increased rates of acute kidney disease (13.5%) and acute coronary syndrome (3.7%) but fewer strokes (4.9%) in the pneumonectomy cohort than in lobectomy patients (7.7%, 2.6%, and 5.6%, respectively, p < 0.001) (Supplementary Table 3 ). 
Survival of Surgical Patients with Multiple Medical Comorbidities
Despite decreased OS after sublobar resection compared with lobectomy in all patients, we sought to determine the impact of lesser anatomic resections on survival of patients with multiple medical comorbidities. We noted that the percentage of surgical patients with a CCI of 2 increased from 2001 to 2010 ( Supplementary  Fig. 6 ). Additionally, for patients with a CCI of 2, there was an absolute 20.1% improvement in 4-year OS from 2001 to 2010 after sublobar resection. This was larger than the corresponding absolute 11.8% 4-year OS increase in the same period after lobectomy. Furthermore, the improvement in survival seen in patients who underwent sublobar resection and had a CCI of 2 was also larger than that seen in patients with a CCI of 0 or 1 (15.9% and 13.3%, respectively) ( Fig. 3B and 3C) . Moreover, by the end of the decade (from 2008 to 2010), patients with a CCI of 2 who were undergoing sublobar excision had a 4-year OS nearly equal to that of those undergoing lobectomy (55.4% versus 58.1%, respectively) (p ¼ 0.69). This was in contrast to the findings in healthier patients (those with a CCI of 0 or 1), for whom a significant 4-year OS benefit to lobectomy over sublobar resection remained over 2008-2010 (68.0% versus 55.5%, respectively [p < 0.001]). Taken together, these data suggest that fewer pneumonectomies, increased utilization of VATS for all patients, and sublobar excision in medically unfit patients improved survival of patients undergoing surgery as a whole.
Impact of Adjuvant Chemotherapy on Survival
Consideration of adjuvant chemotherapy is standard of care for node-negative tumors larger than 4 cm and node-positive tumors. A total of 486 surgical patients (5.8%) had adjuvant chemotherapy. Compared with those who did not receive adjuvant chemotherapy, those who underwent adjuvant chemotherapy showed an improvement in OS (HR ¼ 0.82, 95% CI 0.72-0.92, p ¼ 0.001) (Supplementary Fig. 7A ) but no difference Supplementary Fig. 7B ), suggesting a selection bias of healthier patients for chemotherapy. On Cox multivariate analysis, chemotherapy, along with lobectomy, age, stage, CCI, and tumor grade, were significant for survival after surgery. In addition, treatment era remained significant, indicating an unknown modifier of survival after surgery (Supplementary Table 8 ).
Impact of Treatment Modality on Survival
Finally, we sought to compare the effect of treatment modality (i.e., the effect of surgery or radiation on survival of patients with stage I NSCLC). OS (HR ¼ 0.36, 95% CI: 0.35-0.38, p < 0.001) ( Fig. 8B ) with surgery was maintained with PS matching. As patients who received SBRT had improved LCSS compared with that of CRT patients, we sought to determine how PS-matched patients treated with this modality specifically compared with those treated who underwent lobectomy. OS (HR ¼ 0.51, 95% CI: 0.43-0.60, p < 0.001) (Fig. 4C) and LCSS (HR ¼ 0.46, 95% CI: 0.32-0.65, p < 0.001) (Fig. 4D) were significantly better after lobectomy than after SBRT on PS-matched analysis.
For all patients, on Cox multivariate analysis, a survival benefit was seen with surgery (HR ¼ 0.39, p < 0.001) in addition to increased survival with stage IA versus IB tumors (HR ¼ 0.79, p < 0.001). A CCI of 2 (HR ¼ 1.42, p < 0.001), increasing age (HR ¼ 1.03 per year, p < 0.001), and higher tumor grade (HR ¼ 1.3 for grade 3 versus for grade 1, p < 0.001) were associated with worse OS (Supplementary Table 9 ).
Discussion
We identified a significant improvement in the OS of patients with stage I NSCLC from 2001 to 2010. This included a more than doubling of OS in patients treated with radiation and a similarly large absolute survival improvement in those undergoing surgery. This survival improvement was due to improvements in NSCLC therapies, as those not treated had no change in survival over this decade. We demonstrated improved survival with the introduction of SBRT in patients who received radiation and improved outcomes with increasing use of VATS and sublobar resections, although for surgical patients there are likely other unaccounted for factors. Surgical management of stage I NSCLC remains superior to management with radiation, despite the significant improvement in OS and LCSS with SBRT, according to this analysis.
Although our analysis included veterans whose NSCLC was diagnosed and treated in the VHA, these data are likely to represent cancer outcomes more broadly. Previous studies have shown VHA lung cancer outcomes to be similar to both clinical trial 11 SBRT, which involves the delivery of a few, precisely targeted, large radiation doses, has rapidly become the standard of care for medically unfit patients with stage I NSCLC. 5 As such, the proportion of patients receiving SBRT increased significantly over the period analyzed and was the most common radiation modality in 2010. In addition, SBRT utilization drove the increased OS of patients treated with radiation in this period. Although final reports of randomized studies comparing SBRT with CRT (NCT01014130 and NCT01920789) are needed to confirm these findings, 13 our results clearly find that SBRT is superior to CRT, as was previously suggested by prior studies. [14] [15] [16] OS also improved with surgery, although the driving factor behind this is less clear. Although the utilization of VATS increased significantly and was associated with an OS benefit on univariate analysis, this benefit did not persist on multivariate analysis. However, for patients with medical comorbidities, a VATS procedure or a more limited resection may provide a better risk-benefit ratio than open surgery. Consistent with this, we showed that for patients with a CCI of 2, survival after sublobar resection approached that of lobectomy by the end of the decade. Therefore, the decreased morbidity and mortality of a limited anatomic resection may overcome potentially decreased cancer control. Alternatively, an unmeasurable Will Rogers phenomenon may be occurring secondary to reassortment of these high-risk surgical candidates to less invasive surgical or nonsurgical procedures, increasing the OS of all groups.
Lastly, we found that surgical patients had significantly better OS and LCSS than did those treated with RT in general or SBRT specifically, even in matched cohorts. This is in agreement with prior studies [17] [18] [19] but in contrast to others that have shown no difference in OS with SBRT versus with surgery. 12, 20 This analysis is likely limited by confounders such as lack of nodal assessment and unmeasured health factors, requiring randomized trials to accurately compare these modalities. Three such trials are under way, including a comparison of sublobar resection and SBRT (NCT02468024), a study of high-risk surgical patients (NCT02629458), and a comparison of lobectomy versus SBRT in medically fit patients with comprehensive nodal staging in all patients (the VALOR study).
This study has a number of potential limitations. Despite the large number of patients, potential unknown confounders that may impact our findings exist. For example, we were unable to quantitate supplemental oxygen use and patient performance status. Furthermore, LCSS data are not available after 2011, and truncating follow-up may disproportionately affect patients treated with VATS or SBRT, as this was more common in the latter half of the decade.
Despite these limitations, this study indicates increased survival for patients in whom stage I NSCLC was diagnosed from 2001 to 2010, with associated increased utilization of less invasive surgical procedures and introduction of advanced radiation techniques. Our results indicate that for patients with significant comorbidities, sublobar resection may be equivalent to lobectomy, and future clinical trials should include this population. In addition, phase III data are needed to address the role of SBRT compared with surgical resection for stage I NSCLC.
